Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.65 |
| ▸ | MTOR | P42345 | 16/20 | 0.65 |
| ▸ | ATR | Q13535 | 8/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24381747 | 0.89 | ATM (0.69) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL24381793 | 0.88 | ATM (0.73) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL24381922 | 0.82 | ATM (0.51) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL24381740 | 0.79 | ATM (0.68) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17272534 | 0.79 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL29355614 | 0.79 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL30410610 | 0.79 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17246146 | 0.79 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL24381744 | 0.78 | JAK2 (0.46) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL26801683 | 0.76 | ATM (0.83) | ATMPIK3CAMTORATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| WO-2022096361-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-12 | — | — | WO | disclosed |
| EP-3992191-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | Deutsches Krebsforschungszentrum (DE) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | ATM 1/4885PIK3CA 239/4885MTOR 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.